Zealand Pharma Advances Petrelintide to Phase 3 After Positive ZUPREME-1 Results in Obesity Program

With petrelintide cleared for Phase 3 initiation in H2 2026, Zealand Pharma and partner Roche are moving an amylin analog candidate into late-stage development at a moment when GLP-1 manufacturing constraints are already reshaping how the industry thinks about capacity planning and technology transfer timelines.

The Phase 2 ZUPREME-1 trial delivered double-digit weight reduction with placebo-like tolerability, a profile that, if sustained in Phase 3, would position petrelintide as a differentiated monotherapy rather than a combination add-on. For manufacturing and QA leads, that distinction carries real operational weight: a standalone chronic-weight-management agent entering pivotal trials now will require dedicated process validation packages, stability programs, and supply-chain architecture well ahead of any potential NDA or MAA submission.

Separately, survodutide, Zealand's glucagon/GLP-1 receptor dual agonist developed with Boehringer Ingelheim, posted positive topline data from the 76-week SYNCHRONIZE-1 Phase 3 trial, with participants achieving up to 16.6% weight loss. Two late-stage obesity assets moving in parallel compresses the window for CMC readiness across both programs simultaneously.

On the discovery side, Zealand announced a Cambridge, Massachusetts research hub and an agreement with DCAI to access a world-leading AI supercomputer, infrastructure investments framed under the company's Metabolic Frontier 2030 strategy. For regulatory affairs leads, AI-assisted drug discovery pipelines increasingly intersect with evolving agency expectations around data integrity and model validation, areas where 21 CFR Part 11 and ICH Q10 quality system principles will apply as outputs move toward IND-enabling packages.

Financially, Q1 2026 net operating expenses reached DKK 573 million against negligible revenue, with a cash position of DKK 14.5 billion as of March 31, a reserve that supports the announced USD 200 million share buy-back while sustaining heavy pipeline investment. The burn rate reflects a company in active late-stage execution, not consolidation.

The Phase 3 program start date in H2 2026 sets a concrete planning horizon for the contract manufacturing and QA organizations that will need validated processes, qualified sites, and audit-ready documentation in place before first patient dosing.

Source: Zealand Pharma A/S via GlobeNewswire, May 7, 2026.